Posted: 22 Apr 2015 05:00 AM PDT
Novo
Nordisk today announced that Saxenda® (liraglutide 3 mg) is now
available in the United States (US). Saxenda® is the first glucagon-like
peptide-1 (GLP-1) receptor agonist for weight management, approved in
the US, EU and Canada.
No comments:
Post a Comment